These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

215 related items for PubMed ID: 37926079

  • 1. Shikonin Exerts an Antileukemia Effect against FLT3-ITD Mutated Acute Myeloid Leukemia Cells via Targeting FLT3 and Its Downstream Pathways.
    Zhao MN, Su L, Song F, Wei ZF, Qin TX, Zhang YW, Li W, Gao SJ.
    Acta Haematol; 2024; 147(3):310-324. PubMed ID: 37926079
    [Abstract] [Full Text] [Related]

  • 2. Ningetinib, a novel FLT3 inhibitor, overcomes secondary drug resistance in acute myeloid leukemia.
    Hu C, Zhang Y, Yang J, Xu Y, Deng T, Li Y, Xu S, Wang S, Wang P.
    Cell Commun Signal; 2024 Jul 08; 22(1):355. PubMed ID: 38978049
    [Abstract] [Full Text] [Related]

  • 3. Silvestrol exhibits significant in vivo and in vitro antileukemic activities and inhibits FLT3 and miR-155 expressions in acute myeloid leukemia.
    Alachkar H, Santhanam R, Harb JG, Lucas DM, Oaks JJ, Hickey CJ, Pan L, Kinghorn AD, Caligiuri MA, Perrotti D, Byrd JC, Garzon R, Grever MR, Marcucci G.
    J Hematol Oncol; 2013 Mar 16; 6():21. PubMed ID: 23497456
    [Abstract] [Full Text] [Related]

  • 4. Reversal of acquired drug resistance in FLT3-mutated acute myeloid leukemia cells via distinct drug combination strategies.
    Zhang W, Gao C, Konopleva M, Chen Y, Jacamo RO, Borthakur G, Cortes JE, Ravandi F, Ramachandran A, Andreeff M.
    Clin Cancer Res; 2014 May 01; 20(9):2363-74. PubMed ID: 24619500
    [Abstract] [Full Text] [Related]

  • 5. FLT3 inhibition upregulates HDAC8 via FOXO to inactivate p53 and promote maintenance of FLT3-ITD+ acute myeloid leukemia.
    Long J, Jia MY, Fang WY, Chen XJ, Mu LL, Wang ZY, Shen Y, Xiang RF, Wang LN, Wang L, Jiang CH, Jiang JL, Zhang WJ, Sun YD, Chang L, Gao WH, Wang Y, Li JM, Hong DL, Liang AB, Hu J.
    Blood; 2020 Apr 23; 135(17):1472-1483. PubMed ID: 32315388
    [Abstract] [Full Text] [Related]

  • 6. The antitumor compound triazoloacridinone C-1305 inhibits FLT3 kinase activity and potentiates apoptosis in mutant FLT3-ITD leukemia cells.
    Augustin E, Skwarska A, Weryszko A, Pelikant I, Sankowska E, Borowa-Mazgaj B.
    Acta Pharmacol Sin; 2015 Mar 23; 36(3):385-99. PubMed ID: 25640477
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Natural small molecule triptonide inhibits lethal acute myeloid leukemia with FLT3-ITD mutation by targeting Hedgehog/FLT3 signaling.
    Xu Y, Wang P, Li M, Wu Z, Li X, Shen J, Xu R.
    Biomed Pharmacother; 2021 Jan 23; 133():111054. PubMed ID: 33254022
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. MZH29 is a novel potent inhibitor that overcomes drug resistance FLT3 mutations in acute myeloid leukemia.
    Xu B, Zhao Y, Wang X, Gong P, Ge W.
    Leukemia; 2017 Apr 23; 31(4):913-921. PubMed ID: 27773927
    [Abstract] [Full Text] [Related]

  • 12. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.
    Zhang W, Konopleva M, Shi YX, McQueen T, Harris D, Ling X, Estrov Z, Quintás-Cardama A, Small D, Cortes J, Andreeff M.
    J Natl Cancer Inst; 2008 Feb 06; 100(3):184-98. PubMed ID: 18230792
    [Abstract] [Full Text] [Related]

  • 13. Cabozantinib is selectively cytotoxic in acute myeloid leukemia cells with FLT3-internal tandem duplication (FLT3-ITD).
    Lu JW, Wang AN, Liao HA, Chen CY, Hou HA, Hu CY, Tien HF, Ou DL, Lin LI.
    Cancer Lett; 2016 Jul 01; 376(2):218-25. PubMed ID: 27060207
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Metformin synergizes with gilteritinib in treating FLT3-mutated leukemia via targeting PLK1 signaling.
    Chen M, Shen C, Chen Y, Chen Z, Zhou K, Chen Y, Li W, Zeng C, Qing Y, Wu D, Xu C, Tang T, Che Y, Qin X, Xu Z, Wang K, Leung K, Sau L, Deng X, Hu J, Wu Y, Chen J.
    Cell Rep Med; 2024 Jul 16; 5(7):101645. PubMed ID: 39019012
    [Abstract] [Full Text] [Related]

  • 20. Inhibition of NRF2 signaling overcomes acquired resistance to arsenic trioxide in FLT3-mutated Acute Myeloid Leukemia.
    Jebanesan DZP, Illangeswaran RSS, Rajamani BM, Vidhyadharan RT, Das S, Bijukumar NK, Balakrishnan B, Mathews V, Velayudhan SR, Balasubramanian P.
    Ann Hematol; 2024 Jun 16; 103(6):1919-1929. PubMed ID: 38630133
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.